CRISPR Therapeutics AG, headquartered in Zug, develops gene-based medicines for serious diseases using its CRISPR/Cas9 platform and went public on October 19, 2016. The company focuses on gene editing to treat genetically-defined diseases and enhance cellular therapies.
CRSP has been in the news recently: CRISPR Therapeutics AG reported a financial loss for the first quarter and shared new study results identifying risk factors for atherosclerotic heart disease. Additionally, Vinay Prasad has been appointed as the new director of the FDA's Center of Biologics Evaluation and Research.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
